Acinetobacter Baumannii, which is mostly contracted in hospital stays, has been developing resistance to all available antibiotics, including the last line of drugs, such as carbapenem. Because of its quick adaptation there is an immediate need to design new antibiotics, possibly antimicrobial peptides (AMPs) to which bacteria do not develop resistance easily. Our threefold goal was to curate the available activity of AMPs on the same strain of A. Baumannii, build a neural network model for predicting their activity and use it to rationally pre-screen for lead generation from the thousands of naturally occurring AMPs. By curating and analyzing the recent activity data from 81 AMPs on ATCC 19606 strain, we develop a quantitative AMP activity prediction model. We selected three other models with comparable performance against a test set with known activities. With the goal of inspiring further studies on AMP drug candidates and their rational shortlisting, we made activity predictions for the entire * To whom correspondence should be addressed † Theoretical Science Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bengaluru, India.
database of AMPs using all the models. To handle the uncertainty of training with a small data set, highlighted peptides which had consistent results from all models.
Acinetobacter Baumannii (A. Baumannii) 1 mainly implicated in hospital infections and is responsible for 80% of the infections caused by Acinetobacter species. A. Baumannii can also be found on normal human skin, but it generally does not pose threat towards a healthy person, 2-5 besides the not so frequent skin and soft tissue infection, infection in the surgical site, urinary tract infection etc. 6, 7 In the past 30 years, A. Baumannii has evolved into a multidrug resistant (MDR) [8] [9] [10] opportunistic pathogen that selectively infects seriously ill patients in intensive care unit (ICU), trauma or burn patients. [2] [3] [4] 11 The presence of intrinsic efflux pump and high rates of genetic adaptation, contributes to adaptation against the antibiotics. 12-14 Besides, it also possesses several beta-lactamase genes which offer resistance against beta-lactam antibiotics. 15, 16 A. Baumannii has also been developing resistance against carbapenem 17 which had been one of the last line of drugs against it.
Combination therapies such as of colistin, polymixin B, and tigecycline are used to treat MDR strains, but these are complex compared to a single drug when it comes to quantification of the effect and the validation of their safety. [18] [19] [20] Due to the growing concern about MDR, there is a surge for new types of antimicrobial agents.
Antimicrobial peptides (AMP) are a fundamental part of the innate defense system and are reportedly present in organisms from bacteria and fungus to humans. Several experimental groups have independently evaluated the activity of AMP against A.
Baumannii. The goal of the present work is threefold. We curated these experimental result against a single, well studied, target ATCC 19606 strain. We developed a computational model using neural networks to rationally predict the activity from the biochemical attributes of the AMP. Since A. Baumannii is a growing threat, while realizing the potential limitations of training on 81 peptides, we also predict the activity of all AMPs from the AMP database on the A. Baumannii.
The data on the activity of AMPs on A. Baumannii is scattered in literature. We curated the data mainly with the goal of developing a quantitative model, and hence restricted the focus to the most commonly studied strain. The activity data of AMPs on A. Baumannii ATCC 19606 strain was curated from different sources [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] and is presented in Supplementary Figure 1 and their individual relation with MIC in Figure 1 , which shows that each of the parameters individually is not sufficient to describe the activity. It is important to know, which are the parameters (P i ) that are most responsible for the activity on A. Baumannii. In the combined training and validation set used for accepting the models, we replaced (P i ) with its average <P i > and measure the difference ∆R
is treated as reflecting the importance of Table 1 .
the parameter. The results obtained from Model-1 are given in Figure 3 and those from the other three models are given in Supplementary Figure 3 . From our calculations, we found out that the in vitro aggregation propensity in the most important parameter in Model-1. Considering the health threat A. Baumannii is posing, and the potential of AMPs for antibiotic-resistance-free activity, we propose a rational basis for the design of AMPs for A. Baumannii. Our models were used to predict the MIC values of the 2338 AMPs ob-tained from AMP database [60] [61] [62] (https://aps.unmc.edu). In order to reduce the risk of a poorly trained ANN model with limited data, we filtered the predictions from all models for a consistent prediction that is within ∆MIC≤ 5µg/ml (Supplementary table 3 ).
To our knowledge ours is the only QSAR study for predicting AMP activity against A.
Baumannii. The present work is different from the only the only other QSAR in two different ways, using AMPs in stead of small molecules for a better tolerance to antibiotic resistance and a slightly larger set (81 AMPs compared to 29 small molecules). Using the ANN models we developed, we could make quantitative predictions for the entire database of naturally occuring AMPs. We hope that our work will inspire the further studies quantifying the activity of AMPs on A. Baumannii, some of which may follow the activity predictions and others that differ offer an opportunity to retrain the ANN models. Supplementary Table 2 Supplementary Table 2 : Details of the 12 lower-bound AMP data, these 9 were used for a qualitative test. Before accepting a model, at least 6 of these 9 results were verified to be satisfying the condition and then a quantitative test condition is used with the test data set from the exact data. 
